Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) EBITDA (2023 - 2025)

NewAmsterdam Pharma's EBITDA history spans 3 years, with the latest figure at -$74.8 million for Q4 2025.

  • For Q4 2025, EBITDA rose 18.84% year-over-year to -$74.8 million; the TTM value through Dec 2025 reached -$203.5 million, up 15.76%, while the annual FY2025 figure was -$203.5 million, 15.76% up from the prior year.
  • EBITDA for Q4 2025 was -$74.8 million at NewAmsterdam Pharma, down from -$71.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$16.6 million in Q3 2024 and bottomed at -$93.8 million in Q1 2024.
  • The 3-year median for EBITDA is -$44.6 million (2023), against an average of -$51.8 million.
  • The largest annual shift saw EBITDA skyrocketed 64.68% in 2024 before it crashed 330.66% in 2025.
  • A 3-year view of EBITDA shows it stood at -$49.5 million in 2023, then crashed by 86.14% to -$92.1 million in 2024, then rose by 18.84% to -$74.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's EBITDA are -$74.8 million (Q4 2025), -$71.7 million (Q3 2025), and -$17.5 million (Q2 2025).